Status:
UNKNOWN
RFA Using Combined Bipolar and Monopolar Energy Deliver With Twin Cooled-Wet Electrodes
Lead Sponsor:
Seoul National University Hospital
Conditions:
Radiofrequency Ablation
Carcinoma, Hepatocellular
Eligibility:
All Genders
20-85 years
Phase:
NA
Brief Summary
In this study, a dual / Twin Cooled-wet electrode was used to perform RFA therapy on residual tumors after transarterial chemo-embolization and to find out the therapeutic results. The primary endpoin...
Detailed Description
In the treatment of HCC, local interventional procedures such as transarterial chemo-embolization and RFA are one of the most widely used methods. The probability of complete necrosis is known to be a...
Eligibility Criteria
Inclusion
- agree to the protocol's requirements and submit a consent form
- 20 years old-85 years old
- Child-Pugh Class A and B
- Patients with residual HCC after locoregional treatment who meet the following conditions A. Patients with a single nodular HCC within 5 cm or multiple nodular HCC of 3 or less in all cases of focal cancer B. Patients who did not have vascular invasion or extrahepatic metastasis during locoregional intervention
Exclusion
- When the number of malignant HCC is 3 or more
- If the tumor has a maximum size of 3 cm or more
- diffuse infiltrative HCC
- Child-Pugh class C
- If there is an invasion of liver vessels due to malignant liver tumors
- severe coagulopathy
- multiple distant metastasis
- situations where it is very unlikely to obtain appropriate data for research purposes
Key Trial Info
Start Date :
January 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT04331184
Start Date
January 28 2020
End Date
December 30 2022
Last Update
March 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea